Status:

COMPLETED

Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Conditions:

Ulcerative Colitis

Crohn's Disease

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC o...

Detailed Description

This was a phase 2, multiple-dose, open-label study of vedolizumab administered intravenously (IV) every 8 weeks. The study population included treatment-naïve ulcerative colitis (UC) or Crohn's Disea...

Eligibility Criteria

Inclusion

  • Confirmed and active ulcerative colitis (UC) or Crohn's Disease (CD)
  • Crohn's Disease Activity Index (CDAI) Score of 220 - 450 for participants with CD
  • Partial Mayo score of 2 - 7 for participants with UC
  • Patient should be appropriate candidate for biologic therapy per guidelines
  • Up-to-date on cancer screening
  • No severe systemic disease
  • Patients with evidence of abscess
  • Agree to comply with study procedures including contraception

Exclusion

  • Low lymphocyte counts
  • History of imaging abnormalities, multiple sclerosis (MS), brain tumor or other neurological illness
  • Active or recent serious infections
  • Recent treatment with biologic (i.e., Remicade) or investigational drug
  • Impending surgery
  • Any participants with vedolizumab human anti-human antibody (HAHA) titers ≥1:125 or with a previous immediate hypersensitivity reaction during or shortly after vedolizumab infusion

Key Trial Info

Start Date :

December 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00619489

Start Date

December 1 2007

End Date

March 1 2010

Last Update

July 18 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

London Health Sciences Centre

London, Ontario, Canada